Prime Medicine
(NASDAQ) PRME
Prime Medicine Financials at a Glance
Market Cap
$702.60M
Revenue (TTM)
$4.03M
Net Income (TTM)
-$198.37M
EPS (TTM)
-$1.25
P/E Ratio
-3.10
Dividend
$0.00
Beta (Volatility)
1.97 (High)
Dividend
$0.00
Beta (Volatility)
1.97 (High)
Price
$3.88
Volume
152,615
Open
$3.69
Price
$3.88
Volume
152,615
Open
$3.69
Previous Close
$3.88
Daily Range
$3.62 - $3.95
52-Week Range
$2.67 - $6.94
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.97 (High)
Price
$3.88
Volume
152,615
Open
$3.69
Previous Close
$3.88
Daily Range
$3.62 - $3.95
52-Week Range
$2.67 - $6.94
Estimated Earnings Date
Aug 6, 2026
PRME News
PRME: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Prime Medicine
Industry
Biotechnology
Sector
Health CareEmployees
146
CEO
Allan Jacob Reine, MD
Website
www.primemedicine.comHeadquarters
Cambridge, MA 02139, US
PRME Financials
Key Financial Metrics (TTM)
Gross Margin
-1082.70%
Operating Margin
-5121.76%
Net Income Margin
-4917.55%
Return on Equity
-188.82%
Return on Capital
-87.80%
Return on Assets
-67.31%
Earnings Yield
-32.26%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$702.60M
Shares Outstanding
180.62M
Volume
152.62K
Avg. Volume
2.63M
Financials (TTM)
Gross Profit
-$43.68M
Operating Income
-$206.61M
EBITDA
-$190.90M
Operating Cash Flow
-$156.42M
Capital Expenditure
-$2.32M
Free Cash Flow
-$158.74M
Cash & ST Invst.
$135.50M
Total Debt
$114.51M
Prime Medicine Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$856.00K
-41.1%
Gross Profit
-$1.00M
-168.8%
Gross Margin
-1.17%
N/A
Market Cap
$702.60M
N/A
Market Cap/Employee
$3.28M
N/A
Employees
214
N/A
Net Income
-$49.12M
+5.3%
EBITDA
-$47.27M
+5.8%
Quarterly Fundamentals
Total Cash
$135.50M
-6.1%
Total Debt
$114.51M
-5.5%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$105.97M
-7.3%
Short Term Debt
$8.55M
+24.6%
Return on Assets
-67.31%
N/A
Return on Invested Capital
-79.95%
N/A
Free Cash Flow
-$42.92M
+16.3%
Operating Cash Flow
-$42.71M
+12.6%